Health
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers The investigational drug is designed to be activated in the tumor microenvironment, including in cutaneous squamous cell carcinoma SCOTTSDALE, Ariz., May 20, 2025 (GLOBE NEWSWIRE) -- A common and unsightly skin cancer that can turn deadly has be
About this update from Werewolf Therapeutics, Inc.
[{"type":"text","content":"There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening","length":153,"tagName":"p"},{"type":"text","content":" Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers","length":100,"tagName":"p"},{"type":"text","content":"The investigational drug is designed to be activated in the tumor microenvironment, including in cutaneous squamous cell carcinoma","length":130,"tagName":"p"},{"type":"text","content":"SCOTTSDALE, Ariz., May 20, 2025 (GLOBE NEWSWIRE) -- A common and unsightly skin cancer that can turn deadly has been undetectable for more than a year in a patient treated with a new targeted immune-therapy in a clinical trial at HonorHealth Research Institute.","length":261,"tagName":"p"},{"type":"text","content":"Wayne Futch, 73, of Phoenix, developed a type of skin cancer known as cutaneous squamous cell carcinoma, following a career in pool-maintenance that regularly exposed him to hours of strong sunlight. Despite wearing sunscreen and protective clothing, Mr. Futch’s face was disfigured by skin cancer. He lost his right eye following more than 60 radiation treatments that ultimately failed to rid him of the malignancy. “It disfigured my face,” Mr. Futch said of the cancer and radiation treatment. “I knew I needed to take some different action, because the radiation was not getting rid of it.”","length":594,"tagName":"p"},{"type":"text","content":"It was then that Mr. Futch said he learned of a new clinical trial for his type of skin cancer at HonorHealth Research Institute. He enrolled in the clinical trial in September 2023. Mr. Futch was infused with a new type of drug that substantially shrunk his tumor in just 8 weeks and left him with no detectable cancer after 12 weeks.","length":335,"tagName":"p"},{"type":"text","content":"“I haven’t had any cancer since (the trial). I don’t have any pain, other than the nerve damage done by the radiation,” said Mr. Futch, who after high school hitchhiked to Phoenix from southern California, married and has remained in the Valley of the Sun ever since. “I feel confident that if (the cancer) ever comes back again, that they’ll detect it and get rid of it, because they did it once already.”","length":406,"tagName":"p"},{"type":"text","content"...